We Shouldn't Wait for a Breakthrough in the Covid-19 Pandemic

Gary P. Pisano

Article | Harvard Business Review Digital Articles | May 6, 2020

We Shouldn't Wait for a Breakthrough in the Covid-19 Pandemic

Abstract

The ultimate solutions to the Covid-19 crisis may be big breakthroughs in building massive test and trace capacity and developing vaccines and drug remedies. But in the meantime, we should not ignore the potential cumulative impact of the many small things we already know how to do or might try that together could make a big dent in the current crisis. Big problems typically get tackled through a series of small solutions, each of which on its own may not seem particularly important but that together can have a huge impact. Creating and implementing a “small steps” strategy, however, will require strong leadership.

Keywords: COVID-19; Health Pandemics; Strategy; Leadership;

Format: Electronic

Find at Harvard Read Now

Citation:

Pisano, Gary P. "We Shouldn't Wait for a Breakthrough in the Covid-19 Pandemic." Harvard Business Review Digital Articles (May 6, 2020).

Manufacturing accounts for more than three-quarters of U.S. corporate patents. The competitive shock to this sector emanating from China's economic ascent could in theory either augment or stifle U.S. innovation. Using three decades of U.S. patents matched to corporate owners, we quantify how foreign competition affects domestic innovation. Rising import exposure intensifies competitive pressure, reducing sales, profitability, and R&D expenditure at U.S. firms. Accounting for confounding sectoral patenting trends, we find that U.S. patent production declines in sectors facing greater import competition. This adverse effect is larger among initially less profitable and less capital-intensive firms.

For more than two decades, scientific advances have been driving profound changes in drug discovery and the drug industry itself. This case provides an overview and description of these technical and scientific advances. Written for the nonscientific reader, it may be used as companion reading for other case materials that require basic knowledge of the tools, techniques, and approaches used in the pharmaceutical and biotechnology industries.

The best practices in supply chain and operations management can help health care providers cope with the surge in patients and the supply shortages. They will help them create a comprehensive strategy aimed at both the demand- and supply-side roots of the problem. The purpose of this article is to assist health care leaders and their organizations in anticipating and preempting problems rather than continuing to react to them.

Faculty & Research

We Shouldn't Wait for a Breakthrough in the Covid-19 Pandemic

Abstract

Citation:

About the Author

More from the Author